论文部分内容阅读
目的观察免疫增强剂甘露聚糖肽联合哌拉西林钠舒巴坦钠治疗盆腔炎的疗效及安全性,为盆腔炎的治疗提供临床依据。方法 80例盆腔炎患者随机分为联合治疗组和对照组,联合治疗组采用甘露聚糖肽注射液联合哌拉西林钠舒巴坦钠注射液静脉滴注,对照组单用哌拉西林舒巴坦钠注射液静脉滴注。两组均每天1次,连用3~14 d。结果疗程结束后,联合治疗组治愈率(87.5%)明显高于对照组(75.0%),差异有统计学意义(P<0.05),联合治疗组的总有效率(97.5%)也明显高于对照组(87.5%),差异有统计学意义(P<0.05);联合治疗组不良反应发生率(7.5%)明显低于对照组(15.0%),差异有统计学意义(P<0.05)。结论甘露聚糖肽注射液联合哌拉西林舒巴坦钠注射液治疗盆腔炎的疗效显著优于单独使用哌拉西林舒巴坦钠注射液,且不良反应更少,值得临床推广应用。
Objective To observe the efficacy and safety of immunostimulant mannan peptide and piperacillin sodium and sulbactam sodium in the treatment of pelvic inflammatory disease and provide a clinical basis for the treatment of pelvic inflammatory disease. Methods Eighty patients with pelvic inflammatory disease were randomly divided into the treatment group and the control group. The combination therapy group was treated with mannan polysaccharide injection and piperacillin sodium and sulbactam sodium injection. The control group received piperacillin and sulbactam Sodium injection intravenous infusion. Both groups were daily 1, once every 3 ~ 14 d. Results After the treatment, the cure rate (87.5%) in the combined treatment group was significantly higher than that in the control group (75.0%), the difference was statistically significant (P <0.05), and the total effective rate (97.5%) in the combined treatment group was significantly higher The difference was statistically significant (P <0.05). The incidence of adverse reactions (7.5%) in the combined treatment group was significantly lower than that in the control group (15.0%), the difference was statistically significant (P <0.05). Conclusion Mannan polysaccharide injection combined with piperacillin and sulbactam sodium injection is superior to piperacillin and sulbactam sodium alone in the treatment of pelvic inflammatory disease with less side effects and is worthy of clinical application.